Strong Non-Farm Payroll Data, Barclays and Goldman Sachs Expect Fed to Cut Rates in July

PANews2025/05/03 03:29

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

PANews reported on May 3 that the strong non-farm employment data released on Friday, May 3, led Goldman Sachs and Barclays, two major financial institutions, to independently predict that the next Federal Reserve rate cut might not occur until at least July. Goldman Sachs still expects three rate cuts of 25 basis points each in 2025, in July, September, and December, but also warns that if future employment data remains strong, the timing of the rate cuts could be further delayed.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

华尔街见闻•2026/10/26 05:56

Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

WTI Price Forecast: Slides further below $100.50; bullish potential seems intact

FXStreet•2026/10/26 05:33

European morning quotes - Elections, central bank policies, and earnings reports will be in focus

路透社•2026/10/26 04:41

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20